Dyspepsia - unidentified cause
Exam Tips
- In OSCEs, explicitly separate uninvestigated dyspepsia from confirmed diagnoses and state that symptoms alone poorly predict serious disease.
- Always screen for alarm features (for example weight loss, persistent vomiting, GI bleeding, dysphagia, anaemia, abdominal mass) and escalate for urgent cancer-pathway assessment when present.
- A common UK primary-care approach is either 1 month of full-dose PPI or test-and-treat for H. pylori; if one strategy fails, switch to the other.
- Remember H. pylori test preparation: no PPI for 2 weeks and no antibiotics for 4 weeks before breath or stool antigen testing.
- Drug history is high yield: NSAIDs/aspirin and several cardio-neuro drugs can drive symptoms; correcting iatrogenic causes can be curative.
- See Figure from page X (alarm features and initial management algorithm) when revising viva structure.
Definition
Uninvestigated dyspepsia is a syndrome of upper gastrointestinal symptoms (typically present for at least 4 weeks) in a person who has not yet had endoscopic evaluation. It commonly includes epigastric pain or discomfort, heartburn, acid regurgitation, nausea, or vomiting, and symptom pattern alone does not reliably distinguish benign disease from significant pathology.
Pathophysiology
Dyspepsia is a symptom complex rather than a single disease process. Mechanisms vary by cause and include acid-related mucosal injury (GORD or peptic ulcer disease), Helicobacter pylori-associated inflammation, impaired gastric accommodation, visceral hypersensitivity, delayed gastric emptying, and brain-gut axis amplification (for example with anxiety or stress). Drug-induced dyspepsia may result from direct mucosal irritation (for example NSAIDs) or reduced lower oesophageal sphincter tone/motility effects (for example nitrates, calcium-channel blockers, anticholinergics). See Figure from page X (upper GI symptom-mechanism map).
Risk Factors
- Helicobacter pylori infection
- NSAID or aspirin use
- Smoking
- Higher alcohol intake
- Obesity
- Trigger foods (for example fatty/spicy meals, coffee, chocolate, tomato-based foods)
- Psychological comorbidity (stress, anxiety, depression)
- Drugs that can worsen symptoms (alpha-blockers, anticholinergics, benzodiazepines, beta-blockers, bisphosphonates, calcium-channel blockers, corticosteroids, nitrates, theophyllines, tricyclic antidepressants)
- Family history of upper GI malignancy
Clinical Features
Symptoms
- Epigastric pain or upper abdominal discomfort
- Heartburn
- Acid regurgitation/reflux
- Nausea
- Vomiting
- Postprandial fullness or early satiety
- Bloating
Signs
- Often normal examination
- Epigastric tenderness
- Weight loss on serial measurements (alarm feature)
- Pallor or other signs of anaemia
- Abdominal mass (alarm feature)
Investigations
Management
Lifestyle Modifications
- Weight reduction if overweight/obese
- Avoid personal trigger foods (for example coffee, chocolate, fatty/spicy foods, tomato-rich meals)
- Smaller meals and avoid late evening meals (last meal 3-4 hours before bed)
- Smoking cessation
- Reduce alcohol intake to recommended UK limits
- Address stress/anxiety/depression; consider psychological therapies where appropriate
- Short-term antacid/alginate can be used for intermittent relief, but avoid continuous long-term self-treatment
Pharmacological Treatment
Proton pump inhibitor (empirical first-line strategy)
- Lansoprazole 30 mg once daily for 4 weeks
- Omeprazole 20-40 mg once daily for 4 weeks
- Esomeprazole 20 mg once daily for 4 weeks
- Pantoprazole 40 mg once daily for 4 weeks
- Rabeprazole 20 mg once daily for 4 weeks
Use full-dose PPI for 1 month in uninvestigated dyspepsia. Review response and step down to lowest effective dose if ongoing therapy needed. Safety: long-term PPI use is associated with risks (for example hypomagnesaemia, C. difficile infection, fractures, B12 deficiency, interstitial nephritis), so use the minimum effective duration.
H. pylori eradication (if test positive)
- PPI twice daily + amoxicillin 1 g twice daily + clarithromycin 500 mg twice daily for 7 days
- PPI twice daily + amoxicillin 1 g twice daily + metronidazole 400 mg twice daily for 7 days
- If penicillin allergy: PPI twice daily + clarithromycin 500 mg twice daily + metronidazole 400 mg twice daily for 7 days
Choose regimen based on allergy status and prior macrolide/metronidazole exposure. Counsel strongly on adherence. Safety/contraindications: avoid amoxicillin in true penicillin allergy; clarithromycin has significant CYP3A4 interactions and QT-prolongation risk; metronidazole requires strict alcohol avoidance during treatment and for 48 hours after completion.
Medication optimisation
- Stop or reduce offending medicines where clinically safe (for example NSAIDs, aspirin, bisphosphonates, nitrates, calcium-channel blockers, anticholinergics)
If NSAID-associated symptoms, discontinue NSAID if possible. If antiplatelet/NSAID cannot be stopped, balance GI risk against cardiovascular/rheumatological indications and provide gastroprotection.
Complications
- Missed serious pathology (including upper GI malignancy) if alarm features are not recognised
- Progression of underlying peptic ulcer disease to bleeding or perforation
- Persistent symptoms causing reduced quality of life, sleep disturbance, and repeated healthcare use
- Medication-related adverse effects from prolonged empiric therapy
Prognosis
Most patients improve with lifestyle optimisation, short-course PPI, or targeted H. pylori treatment, but recurrence is common. Prognosis depends on the underlying cause; persistent, recurrent, or alarm-feature dyspepsia requires reassessment and possible endoscopic investigation to exclude significant disease.
Sources & References
💊BNF Drug References(10)
- Co-magaldrox[management.pharmacological]
- Dexketoprofen[contraindications]
- Lansoprazole[management.pharmacological]
- Magnesium carbonate[management.pharmacological]
- Magnesium trisilicate[management.pharmacological]
- Magnesium trisilicate with magnesium carbonate and sodium bicarbonate[management.pharmacological]
- Omeprazole[management.pharmacological]
- Pantoprazole[management.pharmacological]
- Rabeprazole sodium[management.pharmacological]
- Simeticone with aluminium hydroxide and magnesium hydroxide[management.pharmacological]
✅NICE Guidelines(1)
- Dyspepsia - unidentified cause[overview]
📖Textbook References(8)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 677)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 674, 675)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 653)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 269)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 268, 269)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 269)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 269)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1047, 1048)[context]